Naps associated with increased risk of death, report says

June 5 (UPI) -- An afternoon snooze might seem appealing to middle-aged folks and seniors, but these naps could carry a high cost.
People with certain types of napping patterns have a greater risk of an early death, researchers are slated to report at an upcoming meeting of the American Academy of Sleep Medicine.
"People who slept longer during the day, had irregular daytime sleep patterns, or slept more around midday and early afternoon were at greater risk, even after accounting for health and lifestyle factors," lead researcher Chenlu Gao, a postdoctoral research fellow at Massachusetts General Hospital in Boston, said in a news release.
The findings call into question the whole concept of the "power nap."
For the study, researchers analyzed data on more than 86,500 people participating in the UK Biobank long-term health research project.
These folks had their sleep habits monitored for a week using wrist devices, and researchers compared those habits to death records. Their average age was 63 at the time their napping was tracked.
Nearly 5,200 people died during a follow-up of 11 years, researchers said.
Results showed an increased risk of premature death for:
• People who tended to take longer daytime naps
• Folks whose napping patterns fluctuated frequently
• People who napped between 11 a.m. and 3 p.m.
This last observation contradicts academy guidelines, which encourages adults to limit themselves to "power naps" of no more than 20 to 30 minutes in the early afternoon, researchers noted.
Naps that last longer than a half-hour can cause grogginess that undercuts the potential helpfulness of a siesta, researchers said.
"Interestingly, the data that shows risks associated with napping around midday and early afternoon contradicts what we currently know about napping, so further research on that link could be warranted," Gao said.
Gao is to present these findings Wednesday during the AASM's annual meeting in Seattle.
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
The Mayo Clinic has more on napping for healthy adults.
Copyright © 2025 HealthDay. All rights reserved.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

18 minutes ago

• Yahoo

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275

CBS News

43 minutes ago

• CBS News

Rats in Boston may be spreading potentially deadly disease, Tufts University study says

Tufts study says rats in Boston could be spreading potentially deadly disease Tufts study says rats in Boston could be spreading potentially deadly disease Tufts study says rats in Boston could be spreading potentially deadly disease Rats in Boston may be spreading a potentially deadly disease, according to a Tufts University study. The disease is called leptospirosis, which is caused by a bacterium called Leptospira. It is typically found in tropical areas, but a link has been found between rats and leptospirosis in other urban areas. Researchers worked on the study for six years, testing different brown rats from the Boston area, including the Boston Public Garden and Boston Common. They found that most rat populations in Boston carry the disease-causing bacteria, which can infect both humans and animals. Researchers warn that the disease's prevalence is expected to increase with climate change. Leptospirosis is typically spread through direct exposure to urine or a "urine-contaminated environment, which then can serve as an infection source for additional rats and other mammals, including humans," the study says. Leptospirosis can be spread through contact with water, soil, and eating food that has been contaminated with animal urine. The bacteria can survive in both water and soil for months. There are around one million cases of leptospirosis in humans around the world every year, and around 60,000 deaths, according to the CDC. Symptoms of leptospirosis Leptospirosis can be deadly if not treated, causing organ failure, trouble breathing, and death, the CDC says. Symptoms of the disease include: Fever Headache Chills Body aches Rash Diarrhea or vomiting Jaundice Red eyes Seek treatment immediately if you think you may have been infected with leptospirosis. Here are some recommended ways to prevent infection: Avoid contact with potentially infected animals Cover any open wounds, including cuts and scratches Wear waterproof clothing and shoes near floodwater or infected soil Research leptospirosis cases if you intend to go swimming A vaccine for leptospirosis is available in the United States for both cats and dogs. If you are concerned that your pet may have contracted the disease, visit the CDC website for more information.

Yahoo

an hour ago

• Yahoo

David Hopkinson obituary

My friend and former colleague David Hopkinson, who has died aged 89, was director of the Medical Research Council's human biochemical genetics unit at University College London from 1976 until its closure in 2000. Hoppy, as he was universally known, had joined the unit at its inception in 1962 because in an earlier, more junior, position he had been one of the first medical scientists to describe molecular differences in human enzymes, long before DNA sequence differences were known about. The unit was established to research the extent and significance of genetic variation to human health. As its head, Hoppy expanded its focus to gene mapping and disease genetics while also moving into the new science of gene cloning and DNA sequencing. Born in Chesterfield, Derbyshire, to Albert Hopkinson, an iron and steelworks foreman, and Lilian (nee Siddal), a dressmaker, he went to Chesterfield grammar school, which fostered his early interest in organic chemistry. After completing a natural sciences degree at Cambridge University he qualified in medicine at the London hospital in 1959, working there until he joined the human biochemical genetics unit three years later. Hoppy was recruited by its inaugural head, Prof Harry Harris, becoming his right-hand man responsible for many of the unit's innovative experimental approaches, including developing novel methods of enzyme detection and electrophoresis. The unit moved in 1965 from its initial base at King's College to UCL, where I joined the unit three years later to study for a PhD under Harris. Hoppy remained there for the rest of his career. He published widely, and played an important part in teaching and supervision, being made full professor of London University in 1990. Twenty five years after his retirement, his role as mentor is remembered with great warmth by his former staff and students. Hoppy read widely and appreciated drama and music. A practical man who took pleasure in manual labour, he was an accomplished gardener and delighted in propagating plants and growing vegetables. He also enjoyed summers hiking in the Swiss Alps, and was a keen birdwatcher. In retirement, he studied architecture and German, and gained a first-class degree in geology at the Open University. He also spent many years as a volunteer at Chilterns' Citizens Advice in Chesham, Buckinghamshire. He is survived by his second wife, Prof Yvonne Edwards, and by three children, Paul, Susan and Ian, from his first marriage, to Josephine (nee Manze), which ended in divorce, and four grandchildren.